Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Aibotics Therapies Q3 2026 Results: Net Loss of $282K, Loss Narrows

AIBotics Therapies, Inc. reported a net loss of $1,237,486 for the nine months ended September 30, 2026, compared to a net loss of $1,607,467 in the prior year period. The company remains in a significant stockholders' deficit of $4,800,349 and continues to rely on the issuance of common stock and convertible notes to settle liabilities and fund operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Gross profit0.00.0
Profit before tax-0.3-0.5
Net income-0.3-0.5

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: AIBT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aibotics, Inc.: key numbers

Share price
$0.0029Close, Nov 20
Market cap
$2.9M
Shares outstanding
1BLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aibotics, Inc.

All →
4:08 PM ET 8-K
M&A Deal

Aibotics M&A Deal with PlayJamaica Limited

Aibotics, Inc. entered into a definitive agreement to acquire the robotics, drone services, AI, and mapping assets of PlayJamaica Limited for an initial consideration of $225,000 in Series B Preferred Stock. The deal includes an earn-out provision where PlayJamaica can receive up to an additional $3 million in preferred stock based on achieving $5 million in cumulative revenue over four years. Aibotics also committed to deploying $1 million in capital into the newly formed NovaCore Labs subsidiary over the next 12 months.

Counterparty
PlayJamaica Limited
6:01 AM ET 8-K
M&A Deal

Aibotics Signs $22M M&A Deal with Empulser Enterprises LLC

Aibotics Inc. has entered into a definitive agreement to acquire 100% of Empulser Enterprises LLC in exchange for Series C Preferred Stock with an aggregate stated value of up to $22 million. The deal includes an earn-out structure where 90% of the consideration is tied to ten specific milestones over a 36-month period, including patent filings, flight testing, and revenue targets. Upon closing, Empulser will become a wholly owned subsidiary of Aibotics.

Value
$22M
Counterparty
Empulser Enterprises LLC
Term
36 months

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.